Age-specific incidence, treatment, and survival trends in esophageal cancer:a Dutch population-based cohort study

Background: Data on the age-specific incidence of esophageal cancer are lacking. Our aim was to investigate the age-stratified incidence, treatment, and survival trends of esophageal cancer in the Netherlands, with a focus on adults <50 years. Material and methods: Patients diagnosed with esophageal cancer were included from the nationwide Netherlands Cancer Registry (1989–2018). Follow-up data were available until 31 December 2018. Annual percentage changes of incidence were analyzed according to age group (<50, 50–74, and ≥75 years) and histology type: adenocarcinoma (EAC) and squamous... Mehr ...

Verfasser: Al-Kaabi, Ali
Baranov, Nikolaj S.
van der Post, Rachel S.
Schoon, Erik J.
Rosman, Camiel
van Laarhoven, Hanneke W. M.
Verheij, Marcel
Verhoeven, Rob H. A.
Siersema, Peter D.
Dokumenttyp: Artikel
Erscheinungsdatum: 2022
Reihe/Periodikum: Al-Kaabi , A , Baranov , N S , van der Post , R S , Schoon , E J , Rosman , C , van Laarhoven , H W M , Verheij , M , Verhoeven , R H A & Siersema , P D 2022 , ' Age-specific incidence, treatment, and survival trends in esophageal cancer : a Dutch population-based cohort study ' , Acta Oncologica , vol. 61 , no. 5 , pp. 545-552 . https://doi.org/10.1080/0284186X.2021.2024878
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29047408
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://research.vumc.nl/en/publications/7c9f6f14-452a-4100-8605-081c0f6d55a9

Background: Data on the age-specific incidence of esophageal cancer are lacking. Our aim was to investigate the age-stratified incidence, treatment, and survival trends of esophageal cancer in the Netherlands, with a focus on adults <50 years. Material and methods: Patients diagnosed with esophageal cancer were included from the nationwide Netherlands Cancer Registry (1989–2018). Follow-up data were available until 31 December 2018. Annual percentage changes of incidence were analyzed according to age group (<50, 50–74, and ≥75 years) and histology type: adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). Treatment trends and relative survival rates (RSR) were estimated by age and stage grouping. Results: A total 59,584 patients were included. In adults <50 years, EAC incidence tripled (mean increase per year: males 1.5%, females 3%), while the incidence of ESCC decreased (mean decrease per year: males −5.3%, females −4.3%). Patients <50 years more often presented with advanced disease stages compared to older patients and were more likely to receive multimodality treatments. Most patients <50 years with potentially curable disease were treated with neoadjuvant chemoradiotherapy followed by surgery compared to patients 50–74 and ≥75 years (74% vs. 55% vs. 15%, respectively; p <.001), and received more frequent systemic therapy once staged with palliative disease (72% vs. 54% vs. 19%, respectively; p <.001). The largest RSR improvement was seen in patients <50 years with early-stage (five years: +47%), potentially curable (five years: +22%), and palliative disease (one year: +11%). Over time, a trend of increasing survival difference was seen between patients <50 and ≥75 years with potentially curable (five-year difference: 17% to 27%) and palliative disease (one-year difference: 11% to 20%). Conclusion: The incidence of EAC is increasing in adults <50 years in the Netherlands. Differences in the use of multimodality treatments with curative or life-prolonging intent in ...